AstraZeneca Appoints Rich Fante as President of its U.S. Business
WILMINGTON, Del., Nov. 18 /PRNewswire-FirstCall/ -- AstraZeneca
(NYSE: AZN) today announced the appointment of Rich Fante as President of the
company's U.S. business.
Fante takes over from Tony Zook, whose role was expanded after recently
being named President of MedImmune, the wholly owned biologics business for
AstraZeneca PLC. Zook is CEO of AstraZeneca North America and head of global
marketing.
In announcing Fante's appointment, Zook said, "Rich brings strong
leadership and a wealth of experience that is invaluable to our business and
for improving patient health."
Previously, Fante served as AstraZeneca's Vice President, Brand Strategy &
Portfolio Operations. He led the development and execution of marketing
strategies for all AstraZeneca brands in the United States. He has held a
number of leadership roles in his 13 years at AstraZeneca, including Vice
President-Primary Care for the gastrointestinal and respiratory franchises,
including NEXIUM(R) (esomeprazole magnesium) and PULMICORT RESPULES(R)
(budesonide inhalation suspension).
Rich holds a bachelor's degree in biology from Princeton University and a
master's in business administration from the University of North Carolina.
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacturing and marketing of meaningful prescription
medicines and supplier for healthcare services. AstraZeneca is one of the
world's leading pharmaceutical companies with healthcare sales of $29.55
billion and is a leader in gastrointestinal, cardiovascular, neuroscience,
respiratory, oncology and infectious disease medicines. In the United States,
AstraZeneca is a $13.35 billion dollar healthcare business with 12,200
employees committed to improving people's lives. AstraZeneca is listed in the
Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
